Press Release Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan
Press Release BioMarin Announces Results From Phase 2 Clinical Study of 6R-BH4 in Poorly Controlled Hypertension
Press Release BioMarin and Alliant Pharmaceuticals Announce North American Licensing Agreement for Orapred
Press Release BioMarin Announces Offering of $450 Million of 0.599% Senior Subordinated Convertible Notes Due 2024
